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Abstract 
Background: There is a lack of studies regarding the optimal timing for endoscopic retrograde cholangiopancrea‑
tography (ERCP) in patients with cholangitis caused by distal malignant biliary obstruction (MBO). This study aims 
to investigate the optimal timing of ERCP in patients with acute cholangitis associated with distal MBO with a naïve 
papilla.
Methods: A total of 421 patients with acute cholangitis, associated with distal MBO, were enrolled for this study. An 
urgent ERCP was defined as being an ERCP performed within 24 h following emergency room (ER) arrival, and early 
ERCP was defined as an ERCP performed between 24 and 48 h following ER arrival. We evaluated both 30‑day and 
180‑day mortality as primary outcomes, according to the timing of the ERCP.
Results: The urgent ERCP group showed the lowest 30‑day mortality rate (2.2%), as compared to the early and 
delayed ERCP groups (4.3% and 13.5%) (P < 0.001). The 180‑day mortality rate was lowest in the urgent ERCP group, 
followed by early ERCP and delayed ERCP groups (39.4%, 44.8%, 60.8%; P = 0.006). A subgroup analysis showed that in 
both the primary distal MBO group, as well as in the moderate‑to‑severe cholangitis group, the urgent ERCP had sig‑
nificantly improved in both 30‑day and 180‑day mortality rates. However, in the secondary MBO and mild cholangitis 
groups, the difference in mortality rate between urgent, early, and delayed ERCP groups was not significant.
Conclusions: In patients with acute cholangitis associated with distal MBO, urgent ERCP might be helpful in improv‑
ing the prognosis, especially in patients with primary distal MBO or moderate‑to‑severe cholangitis.
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Background
Acute cholangitis is an infection of biliary system as a 
result of biliary stasis [1]. This can be life-threatening 
without timely intervention, such as biliary drainage and 
adequate antibiotics [1–5]. Early endoscopic retrograde 
cholangiopancreatography (ERCP) done within 48  h in 
patients with moderate-to-severe cholangitis is known 
to reduce the duration of hospitalization, mortality rates, 
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and adverse events, such as multiple organ failure [3–7]. 
The most common cause of obstruction is choledocho-
lithiasis, which accounts for about half of the cases [7–9]. 
Malignant biliary obstruction (MBO), such as pancreatic 
cancer, cholangiocarcinoma, or metastatic cancer, consti-
tutes 10–30% of cholangitis cases [3, 5, 7–9].
Patients with biliary stones and those with MBO show 
different clinical courses and prognoses. Cholangitis 
caused by biliary stones can be definitely treated by bil-
iary drainage and removing the stones [10]. On the other 
hand, patients with malignant biliary stricture require 
additional treatment for the underlying disease follow-
ing adequate biliary decompression. Because patients 
with MBO are usually treated with chemotherapy for the 
underlying disease, most patients have poor oral intake, 
poor performance status, and are susceptible to infec-
tion [11–13]. According to a recent study of patients with 
acute cholangitis by Parikh et al. [14] MBO is associated 
with a higher risk of readmission within 30 days. MBO is 
often combined with anatomical alteration in the gastro-
intestinal tract, which can make insertion and cannula-
tion difficult [15, 16]. The stage of cancer also affects the 
prognosis. Unlike patients with early-stage cancer, which 
can be treated curatively, the prognosis for patients with 
MBO caused by metastatic cancer is worse, regardless of 
adequate biliary drainage [17].
Previous studies emphasizing the role of early ERCP 
have been based on populations with heterogeneous eti-
ologies and mostly included patients with biliary stones 
[8, 18, 19]. In a study by Tan et al. [19] 45% of all chol-
angitis was caused by common bile duct stones, and 43% 
by MBO. Another study by Kiriyama et  al. [8] is based 
on patients with various etiologies. The current Tokyo 
Guidelines recommend early or urgent ERCP, depending 
on the severity, but they do not mention the etiology [20].
To date, there is a lack of studies regarding the optimal 
timing for ERCP in patients with cholangitis caused by 
distal MBO. The purpose of this study is to evaluate the 
outcomes according to the timing of ERCP in patients 
with acute cholangitis due to distal MBO.
Methods
Patients and enrollment criteria
This is a retrospective study at Seoul National Univer-
sity Hospital. From January 2005 to June 2018, we ana-
lyzed 1,804 patients who had visited the emergency 
room (ER) and had undergone ERCP for suspected 
biliary obstruction. The 10th edition of the Interna-
tional Classification of Diseases (ICD-10) codes and 
pathologic reports were reviewed to identify patients 
with MBO. Patients with biliary stones or other benign 
etiologies were excluded. Patients who had been dis-
charged from the ER right after ERCP and had received 
outpatient department-based treatment were also 
excluded. We identified 754 patients as MBO patients 
with a naïve papilla after we had excluded those who 
had previously undergone endoscopic sphincter-
otomy, percutaneous transhepatic biliary drainage, 
or endoscopic ultrasound-guided biliary drainage. 
After excluding patients with hilar obstruction and 
those without cholangitis, a total of 421 patients were 
included (Fig. 1). This study was approved by the Insti-
tutional Review Board of Seoul National University 
Hospital, Seoul, Korea (1802-123-924).
Data collection and definitions
Demographic data, including age, sex, and comorbidi-
ties was collected. Patient complaints were investigated 
at the time of ER arrival, and vital signs, including blood 
pressure, body temperature, respiratory rate, heart rate, 
and oxygen saturation were measured. Laboratory find-
ings, including white blood cell count, platelet count, 
C-reactive protein, total bilirubin, albumin, aspartate 
transaminase, alanine transaminase, alkaline phos-
phatase, gamma glutamyl transpeptidase, creatinine, 
and prothrombin time were obtained. If, based on the 
patient’s symptoms and laboratory findings, the biliary 
tract obstruction was suspicious, computed tomog-
raphy scans covering the biliary tree were performed. 
The diagnosis of MBO was based on the obstructive 
patterns of the liver function test, concurrent with bile 
duct strictures on the imaging findings. Cholangitis 
was defined and graded according to the 2018 Tokyo 
Guidelines [20]. Previous anticancer treatments, such 
as curative surgery, chemotherapy, or radiation therapy 
were investigated. Following ERCP, the cancer status 
was assessed, and treatment types, including surgery 
and palliative chemotherapy, were investigated. Death 
data was collected from the Korean Ministry of the 
Interior and Safety database.
Urgent ERCP was defined as ERCP performed within 
24  h, and early ERCP was defined as ERCP performed 
between 24 to 48 h following ER arrival [20]. ERCP per-
formed after 48  h was defined as delayed ERCP [21]. 
The physicians decided when to perform ERCP based 
on the condition of patients including the moderate to 
severe cholangitis. MBO was classified as primary and 
secondary distal MBO, according to the origin of biliary 
obstructive lesion. Primary distal MBO was defined as a 
cancer originally located in the pancreatic head, bile duct, 
ampulla of Vater, periampullary duodenum, or the gall-
bladder directly invading the mid-to-distal CBD; whereas 
secondary distal MBO was defined as any other cancer 
with metastasis to the peribiliary lymph nodes and soft 
tissues.
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Procedures
All ERCPs were performed under moderate sedation 
using midazolam and meperidine. Side-viewing duo-
denoscopes were used (TJF-260, JF-260, TJF-240, JF-240, 
TJF-200, and JF-200; Olympus Optical, Tokyo, Japan). 
After cannulation of the ampulla of Vater, sphincterot-
omy was performed at the discretion of the performing 
clinicians. Contrast was injected after the cannulation, 
and fluoroscopic findings were obtained to evaluate the 
biliary tree. Once the obstructive level had been identi-
fied, the clinician passed guidewire to the upstream part 
of the bile duct obstruction, and inserted a plastic stent 
and/or self-expandable metal stent. If a tight biliary 
stricture was expected, the stent was inserted following 
balloon dilatation at the stricture site.
Study outcome measures
The primary study outcomes were the 30-day mortal-
ity rate and the 180-day mortality rate between those 
patients who had undergone urgent, early or delayed 
ERCP. Secondary outcomes were the technical success 
rate, the clinical success rate, differences in hospital stay, 
and postprocedural adverse events, such as pancreatitis, 
bleeding, and perforation. Technical success was defined 
as a successful deployment of biliary stents at the stric-
ture site on the first ERCP. Clinical success was defined 
Fig. 1 Flowchart of patient enrollment
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as ≥ 30% decrease in total bilirubin over a four-week 
period [22]. Post-ERCP adverse events were based on the 
lexicon guidelines of the American Society for Gastroin-
testinal Endoscopy [23].
Statistical analysis
Continuous variables were expressed as a mean (± stand-
ard deviation) or a median (with interquartile range), 
and categorical variables as numbers and percentages. 
Student’s t test, pairwise Wilcoxon rank sum test, or 
Kruskal–Wallis rank sum test was used for comparison of 
continuous variables between the groups. Pearson’s chi-
square test or Fisher’s exact test was used for compari-
son of categorical value. Post hoc analysis was performed 
using the Bonferroni method. In addition, a multivari-
able analysis was conducted to assess the possible risk 
factors for primary outcomes with p-values ≤ 0.1 in the 
univariable analysis and to adjust for age, sex and ER visit 
during holidays. Akaike Information Criterion-based 
backward selection was used in the multivariable logistic 
regression analysis [24]. All statistical analyses were con-
ducted using the R s/w environment (version 3.6.3; The 
R Foundation for Statistical Computing, Vienna, Austria), 




Table 1 summarizes the baseline characteristics. Urgent, 
early, and delayed ERCPs were performed in 231 (54.9%), 
116 (27.6%) and 74 (17.6%) patients, respectively. The 
median time from ER arrival to ERCP was 24.0 (13.2–
44.7) hours for mild (n = 86), 22.2 (7.2–30.6) hours for 
moderate (n = 289), and 25.9 (18.4–43.4) hours for severe 
(n = 46) grade of cholangitis, and there was no significant 
difference between them (P = 0.087). Prior to the initial 
ERCP, 135 (32.1%) and 52 (12.4%) patients had received 
either palliative systemic chemotherapy or curative resec-
tion for underlying malignancy, respectively. Among 421 
patients, technical success was achieved in 348 patients. 
Plastic stents were used for 173 patients and metal stents 
were used for 175 patients. Twelve patients required 
balloon dilatation for stent insertion due to tight biliary 
stricture, while no patient received bougination for their 
biliary stricture.
The median time before the procedure was 23.1 (8.4–
33.0) hours, 11.8 (5.5–20.9) hours in urgent group, 28.6 
(25.9–36.4) hours in early group, and 70.9 (53.5–98.8) 
hours in the delayed ERCP group (P < 0.001). There 
were no significant differences in age, sex, primary can-
cer location, Charlson’s Comorbidity Index (CCI), the 
proportion of primary MBO, cholangitis severity, the 
type of biliary stent, and the need for balloon dilata-
tion between the three groups. Table  2 summarizes 
the differences in baseline characteristics between the 
patients in the urgent, early, and the delayed ERCP 
groups.
Table 1 Baseline characteristics
MBO malignant biliary obstruction, GI gastrointestinal, CRP C-reactive protein, 
AST aspartate transaminase, ALT alanine transaminase, ALP alkaline phosphatase, 
GGT gamma glutamyl transpeptidase, PT prothrombin time, INR international 
normalized ratio
a Was defined according to the Tokyo Guidelines of 2018
Variables (N = 421)
Age 67.0 (59.0–73.0)
Sex
 Male 251 (59.6%)
 Female 170 (40.4%)
Etiology of MBO
 Biliary tract 184 (43.7%)
 Pancreas 150 (35.6%)
 Upper GI tract 35 (8.3%)
 Lower GI tract 21 (5.0%)
 Lung 10 (2.4%)
 Genitourinary tract 8 (1.9%)
 Breast 6 (1.4%)
 Liver 5 (1.2%)
 Others 2 (0.5%)
Underlying disease
 Hypertension 192 (45.6%)
 Diabetes mellitus 99 (23.5%)
 Cardiovascular disease 32 (7.6%)
 Chronic liver disease 26 (6.2%)
 Chronic kidney disease 5 (1.2%)
 Chronic obstructive pulmonary disease 10 (2.4%)
Primary MBO 341 (81.0%)
Cholangitis  severitya
 Mild 86 (20.4%)
 Moderate 289 (68.6%)
 Severe 46 (10.9%)
Previous upper GI surgery 15 (3.6%)
Initial laboratory findings
 White blood cell,  103/µL 8.0 ± 3.8
 Platelet,  103/μL 245.2 ± 103.1
 CRP, mg/dL 5.8 ± 5.7
 Creatinine, mg/dL 0.8 ± 0.6
 Albumin, g/dL 3.2 ± 0.5
 Total bilirubin, mg/dL 7.9 ± 6.4
 AST, IU/L 122.1 ± 138.9
 ALT, IU/L 146.8 ± 134.5
 ALP, IU/L 461.4 ± 306.0
 GGT, IU/L 674.7 ± 518.8
 PT (INR) 1.1 ± 0.2
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The differences in 30‑day and 180‑day mortality rates 
between each study group
The 30-day mortality rate was lowest in the urgent 
ERCP group, followed by the early and delayed ERCP 
groups (2.2%, 4.3%, 13.5%; P < 0.001). In the post hoc 
analysis, the 30-day mortality in the urgent ERCP group 
was significantly lower than in the delayed ERCP group 
(P = 0.001), whereas the difference between early and 
delayed ERCP groups was not significant (P = 0.084). 
The differences in the 180-day mortality rate between 
the urgent, early, and delayed ERCP groups were also 
significant (39.4%, 44.8%, 60.8%; P = 0.006). In the post 
hoc analysis, the urgent ERCP group showed a signifi-
cantly lower mortality rate as compared to the delayed 
ERCP group (P = 0.006), but the early ERCP group did 
not (P = 0.112). Figure  2 demonstrates the differences 
in both the 30-day and 180-day mortality rates in each 
study group.
Table  3 shows the result of a multivariable analysis, 
which revealed that urgent ERCP (OR 0.11 [0.03–0.34]; 
P < 0.001), early ERCP (OR 0.23 [0.07–0.75]; P = 0.015) 
and secondary MBO (OR 3.33 [1.22–9.06]; P = 0.019) 
are associated with a 30-day mortality rate. Table  4 
demonstrates that a 180-day mortality rate is signifi-
cantly associated with urgent ERCP (OR 0.41 [0.23–
0.72]; P = 0.002), early ERCP (OR 0.54 [0.29–1.00]; 
P = 0.049), and secondary MBO (OR 4.39 [2.52–7.63]; 
P < 0.001) in the multivariable analysis.
Neither the type of biliary stent (P = 0.145) nor the 
need for biliary dilation (P = 0.560) were significantly 
associated with the 30-day mortality rate. However, 
the use of metal stent for biliary drainage was associ-
ated with the increased 180-day mortality rate (OR 
9.99 [6.04–16.52]; P < 0.001), while the need for balloon 
dilatation was not significantly associated with a 180-
day mortality rate (OR 1.76 [0.55–5.65]; P = 0.340).
Among 20 patients who died within 30 days after ERCP, 
there were 12 patients whose cause of death could be 
identified. The most common cause of death was disease 
progression (8 patients, 66.7%), followed by infection 
other than cholangitis (3 patients, 25%), and uncontrolled 
benign gastric ulcer bleeding (1 patient, 8.3%). The cause 
of 180-day mortality, however, was hardly identifiable. In 
most of patients who died within 180  days after ERCP, 
we were not able to determine the cause of death (137 
patients, 72.9%).
Subgroup analysis based on the etiology and severity 
of cholangitis
In the subgroup analysis, the difference in the 30-day 
mortality rates between the urgent, early, and delayed 
ERCP groups was significant in the primary MBO 
group (1.6%, 3.1%, 10.7%; P = 0.007, Additional file  1) 
and in the moderate-to-severe cholangitis group (2.7%, 
5.5%, 17.9%; P < 0.001). The 180-day mortality rates also 
showed significant differences between the urgent, early, 
and delayed ERCP groups in the primary MBO patients 
(31.7%, 40.6%, 53.6%; P = 0.010, Additional file 2) and the 
moderate-to-severe cholangitis patients (39.9%, 49.5%, 
62.5%; P = 0.009). In the post hoc analysis, the differ-
ence between the urgent and delayed ERCP groups was 
significant in all subgroups. Early ERCP, however, did not 
show any significant differences from delayed ERCP in all 
subgroups. Patients with secondary MBO or mild chol-
angitis did not show significant differences in the 30-day 
(secondary MBO: 4.8%, 10.0% 22.2%; P = 0.094, mild 
cholangitis: 0.0%, 0.0%, 0.0%, P > 0.999) and the 180-day 
mortality rates within all study groups (secondary MBO: 
Table 2 Differences in baseline characteristics between the urgent, early, and elective ERCP groups
ERCP endoscopic retrograde cholangiopancreatography, MBO malignant biliary obstruction, GI gastrointestinal, CCI Charlson’s comorbidity index, ER emergency room
a Was defined according to the 2018 Tokyo Guidelines
b Also included the day before holidays
Variables Urgent ERCP (N = 231) Early ERCP (N = 116) Delayed ERCP (N = 74) P value
Age 67.0 (59.0–73.0) 67.0 (60.0–73.0) 66.0 (59.0–72.0) 0.967
Sex 0.858
 Male 139 (60.2%) 70 (60.3%) 42 (56.8%)
 Female 92 (39.8%) 46 (39.7%) 32 (43.2%)
CCI 5.5 ± 1.7 5.5 ± 1.8 5.9 ± 1.9 0.223
Primary MBO 189 (81.8%) 96 (82.8%) 56 (75.7%) 0.428
Cholangitis  severitya 0.536
 Mild 43 (18.6%) 25 (21.6%) 18 (24.3%)
 Moderate to severe 188 (81.4%) 91 (78.4%) 56 (75.7%)
Previous upper GI surgery 10 (4.3%) 4 (3.4%) 1 (1.4%) 0.484
ER arrival at  holidaysb 45 (19.5%) 37 (31.9%) 48 (64.9%)  < 0.001
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73.8%, 65.0% 83.3%; P = 0.468, mild cholangitis: 37.2%, 
28.0%, 55.6%; P = 0.182).
Secondary outcomes according to the timing of ERCP
Table  5 summarizes the differences in secondary out-
comes among the three study groups classified by ERCP 
timing. The overall technical success rate was 82.7%, 
and the differences between each ERCP group were not 
significant (P = 0.120). The clinical success rate in the 
overall cohort was 75.1%, and the urgent ERCP group 
showed the highest clinical success rate, followed by 
the early and delayed ERCP groups (80.1%, 75.0% and 
59.5%; P = 0.002). Adverse events related to the proce-
dure were observed in 31 patients (7.4%); pancreatitis 
in 22 (5.2%), bleeding in 8 (1.9%), and perforation in 
Fig. 2 The difference in 30‑day mortality rate (a) and 180‑day mortality rate (b) between urgent, early and delayed ERCP groups
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1 (0.2%) patient. There were no significant differences 
in procedure-related adverse events between any of 
the study groups. Overall, the mean hospital stay was 
12.1 ± 19.2  days, and there were no significant differ-
ences in any of the ERCP groups (P = 0.337).
Discussion
There is limited data evaluating the optimal timing of 
ERCP in patients with cholangitis caused by distal MBO. 
In this study, we analyzed the outcomes of urgent or early 
ERCP in acute cholangitis due to distal MBO. This study 
found that urgent ERCP clearly improved the 30-day 
Table 3 Univariable and multivariable analysis identifying factors related to 30‑day mortality
ERCP, endoscopic retrograde cholangiopancreatography; MBO, malignant biliary obstruction, ER: emergency room
Univariable Multivariable
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age ≥ 75 0.40 (0.04–1.70) 0.270
Male sex 2.83 (0.93–8.60) 0.095 2.88 (0.90–9.20) 0.074
Timing of ERCP
  > 48 h 1 (Reference)
 24–48 h 0.084 0.23 (0.07–0.75) 0.015
  < 24 h 0.001 0.11 (0.03–0.34)  < 0.001
Secondary MBO 3.04 (1.04–8.42) 0.035 3.33 (1.22–9.06) 0.019
Mild cholangitis 0.00 (0.00–0.76) 0.019 0.00 (0.00‑infinity) 0.987
ER arrival at holidays 1.52 (0.61–3.82) 0.511
Table 4 Univariable and multivariable analysis identifying factors related to 180‑day mortality
ERCP endoscopic retrograde cholangiopancreatography, MBO malignant biliary obstruction, ER emergency room
Univariable Multivariable
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age ≥ 75 0.62 (0.38–1.00) 0.066 0.61 (0.36–1.02) 0.060
Male sex 0.96 (0.65–1.42) 0.907
Timing of ERCP
  > 48 h 1 [Reference]
 24–48 h 0.112 0.54 (0.29–1.00) 0.049
  < 24 h 0.006 0.41 (0.23–0.72) 0.002
Secondary MBO 4.62 (2.68–7.95)  < 0.001 4.39 (2.52–7.63)  < 0.001
Mild cholangitis 0.72 (0.45–1.17) 0.233 0.59 (0.35–1.01) 0.056
ER arrival at holidays 0.91 (0.60–1.38) 0.742
Table 5 Secondary outcomes between three groups classified by duration to ERCP
ERCP endoscopic retrograde cholangiopancreatography
Urgent ERCP (N = 231) Early ERCP (N = 116) Delayed ERCP (N = 74) P value
Success rate
 Technical 198 (85.7%) 94 (81.0%) 56 (75.7%) 0.120
 Clinical 185 (80.1%) 87 (75.0%) 44 (59.5%) 0.002
Post‑ERCP adverse events
 Pancreatitis 13 (5.6%) 5 (4.3%) 4 (5.4%) 0.871
 Bleeding 5 (2.2%) 3 (2.6%) 0 (0.0%) 0.404
 Perforation 1 (0.4%) 0 (0.0%) 0 (0.0%) 0.662
Hospital stay 11.1 ± 22.1 12.1 ± 12.7 14.9 ± 18.1 0.337
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mortality rate and the 180-day mortality rate, especially 
in patients with primary MBO and moderate-to-severe 
cholangitis.
Even without considering the etiology, the optimal tim-
ing of ERCP in patients with acute cholangitis remains 
controversial. In a recent meta-analysis, in-hospital 
mortality was reduced when ERCP had been performed 
within 24  h as compared to after 24  h, within 48  h as 
compared to after 48 h, within 72 h as compared to after 
72  h [25]. Another recent meta-analysis also demon-
strated the beneficial effect of urgent or early ERCP on 
30-day mortality [4]. These studies, however, were not 
able to separate the survival benefits to patients who 
had received urgent ERCP and early ERCP, because the 
mortality data for patients who had undergone ERCP 
between 24 and 48  h was reported inconsistently. We 
divided this study group into three independent groups 
according to the timing of the ERCP, and we selected the 
30-day and 180-day mortality rates as the primary out-
comes, taking into account the subsequent treatments 
such as chemotherapy and curative surgery. The urgent 
ERCP group showed a significant improvement in both 
the 30-day mortality rate and 180-day mortality rate over 
the delayed ERCP group. Meanwhile, the differences in 
the 30-day and 180-day mortality rates between early and 
delayed ERCP groups were not statistically significant. 
This may be because of the nature of early ERCP but may 
also be because of an insufficient sample size.
In the Tokyo Guidelines, urgent or early ERCP is rec-
ommended for patients with moderate-to-severe cholan-
gitis, and a large-scale observational study showed that 
urgent and early ERCP improved 30-day mortality in 
patients with moderate cholangitis [8]. In the case of mild 
cholangitis, however, biliary drainage should be consid-
ered when the initial supportive treatment shows insuf-
ficient response [20, 26]. Our study found that the urgent 
ERCP improved the 30-day mortality rate, as well as the 
180-day mortality rate, in moderate-to-severe cholangi-
tis due to distal MBO. This implies that urgent ERCP can 
increase short-term and medium-term survival rates in 
the moderate-to-severe cholangitis group by minimiz-
ing disruption of subsequent treatment, including cura-
tive surgery and palliative chemotherapy for underlying 
malignant disease. Meanwhile, this survival benefit was 
limited in patients with mild cholangitis.
In this study, urgent ERCP improved the 30-day and 
180-day mortality rates in the primary distal MBO group, 
whereas the differences of 30-day and 180-day mortality 
rates were not significant in the secondary distal MBO 
group. This indicates that urgent ERCP in the primary 
distal MBO group can improve both the short-term and 
medium-term outcomes by enabling a timely imple-
mentation of subsequent anticancer treatment, such as 
curative surgery and chemotherapy. In the secondary 
distal MBO group, however, these anticancer treatment 
attempts were difficult, even though biliary drainage was 
successful.
Because of anatomical alteration associated with tumor 
invasion or previous surgery, endoscopic access to the 
bile duct can be difficult in patients with distal MBO [15, 
16, 27]. In a study of patients with distal MBO due to 
pancreatic head cancer, adequate drainage was successful 
in 75% of the cases in the first ERCP trial [28]. Although 
some randomized controlled trials reported a technical 
success rate of 90% or higher, few or no patients with a 
history of previous upper gastrointestinal surgery were 
included, and no information on previous ERCP history 
was available [27, 29]. In the present study, the technical 
success rate was not inferior to previous studies, consid-
ering that some of the included patients had anatomical 
alterations due to previous surgery, and all patients with a 
previous ERCP history were excluded.
In this study, patients who visited ER on holidays 
tended to receive ERCP later, because the timing of 
ERCP was determined by each physician. In univariable 
and multivariable analysis, however, there were no sig-
nificant differences in 30-day and 180-day mortality rates 
between those who visited on weekdays and weekends. 
This indicates that patients who needed the urgent biliary 
drainage were treated appropriately by the doctor’s deci-
sion, regardless of the day of the hospital visit.
The doctors in this study preferred plastic stents when 
there was a possibility of curative treatment, and used 
metal stents when palliative chemotherapy or supportive 
care was expected. This tendency may affect the better 
180-day mortality rate in plastic stent group.
There are several limitations in this study. First, this 
retrospective, single-center study may have inher-
ent selection bias. Second, about half of the patients 
(54.9%) underwent urgent ERCP following ER arrival, 
resulting in a smaller sample size of early and delayed 
ERCP groups. Caution needs to be applied when inter-
preting the results of subgroup analysis. Third, since 
more than half of the patients had not been diagnosed 
with cancer before ER arrival, comprehensive investiga-
tion of the Eastern Cooperative Oncology Group per-
formance status could not be made at the time of ERCP. 
Instead, this study evaluated the CCI, and provided 
information on the underlying disease status. Fourth, 
a variety of carcinomas were included in each group. 
Staging systems, treatment protocols, and prognoses 
are largely different for each cancer. This heterogeneity 
may serve as a confounding factor in outcomes analy-
sis. Fifth, some clinical information, such as the cause 
of death, could not be analyzed because this was not 
accessible in the government data. Nevertheless, this 
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study has the strength that it demonstrates therapeu-
tic outcomes of urgent ERCP for acute cholangitis in 
patients with only distal MBO.
Conclusions
In conclusion, urgent ERCP might be performed 
actively in acute cholangitis caused by distal MBO con-
sidering the severity and etiology of the MBO. Well-
designed larger prospective randomized controlled 
trials are needed to evaluate the optimal timing of 
ERCP in patients with acute cholangitis due to distal 
MBO.
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